RACAP is a financial services firm specializing in capital allocation strategies and portfolio management solutions. The company leverages advanced analytics and market insights to optimize investment decisions for its clients.

RACAP

NEXTBio Capital invests in breakthrough medicine through application of next-generation technologies.

NEXTBio Capital

Visionary Ventures is a venture capital fund focused on investing in companies from series A to commercialization, aiming for investments that yield exceptional returns and address unmet or underserved markets. The company collaborates with Key Opinion Leaders and industry experts to inform their investment decisions.

Visionary Ventures

Life Science District S.r.l is involved in venture building and corporate innovation within the life sciences sector, focusing on the development, launch, and nurturing of start-ups to enhance health outcomes. The company supports intrapreneurship programs and open innovation strategies for corporates and SMEs.

Life Science District S.r.l

RA Capital Management® (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital® to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization.At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides RA Capital’s investment team and portfolio companies with strategic intelligence, market research, and other resources. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability.

Vor Biopharma

Wave Life Sciences

Shockwave Medical

G1 Therapeutics

Global Blood Therapeutics

Graphite Bio

Imara

Solid Biosciences

Spero Therapeutics

Stoke Therapeutics

Vaxcyte

T2 Biosystems

Tenaya Therapeutics

Crinetics Pharmaceuticals

Cybin

Cyteir Therapeutics

Day One Biopharmaceuticals

Nimbus Therapeutics

Novavax

Pardes Biosciences

Point Biopharma

Janux Therapeutics

Kala Pharmaceuticals

KalVista Pharmaceuticals

Legend Biotech

Lyra Therapeutics

Moderna

Natera

Acrivon Therapeutics

Invivyd

Agile Therapeutics

Akouos

AN2 Therapeutics

Arcutis Biotherapeutics

Ardelyx

Ascendis Pharma

Third Harmonic Bio

Verve Therapeutics

Athersys

Dice Therapeutics

FORMA Therapeutics

Biohaven Pharmaceutical

Black Diamond Therapeutics

Bluebird Bio

Blueprint Medicines

Bolt Biotherapeutics

Bristol-Myers Squibb

Century Therapeutics

Cerevel Therapeutics

Nautilus Biotechnology

New Amsterdam Pharma

Coherus Biosciences

Sierra Oncology

EyePoint Pharmaceuticals

RA Capital Management

Metric
Company Name	RACAP	NEXTBio Capital	Visionary Ventures	Life Science District S.r.l
Symbol
MSH ID	COM:RACAP	COM:NEXTBIOCAPITAL	COM:VISIONARYVC	NET:LSDGROUP
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance	Healthcare & Health Services
Industry	Financial Services	Biotechnology	Venture Capital	Life Sciences
Country	US	US	US	IT
Stage
Employee Count	179
Website	racap.com	nextbiocapital.com	visionaryvc.com	lsdgroup.net
LinkedIn	ra-capital-management-llc			lsd-group
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RACAP

RACAP

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue